Key result
Physical exercise significantly mitigated doxorubicin-induced cardiotoxicity in animal models compared with nonexercised controls, but clinical data are insufficient to establish cardioprotection.
Why the study?
Physical exercise might protect against doxorubicin-induced cardiotoxicity, but its effect and underlying mechanisms needed systematic evaluation using clinical and preclinical evidence.
Does physical exercise prevent doxorubicin-induced cardiotoxicity in clinical and preclinical models?
Comparison
Exercise interventions vs nonexercised controls
Design
Systematic review and meta-analysis
Loading...
Preclinical data support exercise mitigating doxorubicin cardiotoxicity; leaves open clinical efficacy pending larger human trials.
Meta-Analysis
Does physical exercise prevent doxorubicin-induced cardiotoxicity in clinical and preclinical models?
Preclinical evidence strongly supports exercise for mitigating doxorubicin-induced cardiotoxicity, but robust clinical trials are still needed to confirm this effect in patients with cancer.
A 2021 study conducted a meta-analysis in doxorubicin-induced cardiotoxicity. Physical exercise vs. nonexercised controls was evaluated on doxorubicin-induced cardiotoxicity. Physical exercise significantly mitigated doxorubicin-induced cardiotoxicity in animal models compared with nonexercised controls, but clinical data are insufficient to establish cardioprotection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: